Connect with us

Health

Insys Therapeutics Inc (NASDAQ:INSY) Engages First Corporate Communications Leader

Published

on

Insys Therapeutics Inc

Insys Therapeutics Inc (NASDAQ:INSY) reported the recruitment of Joe McGrath as the firm’s Senior Director of Corporate Communications. The company also announced the retention of the Alpha IR Group as its investor relations firm of record.

The details

Prior to joining Insys, McGrath was associated with public relations and corporate communications unit at Medtronic for as many as 16 years. He worked in a succession of functional profiles for the cardiovascular and neurological divisions. In his new role, McGrath is responsible for conducting and directing external and internal communications for the firm, including reputation management, corporate brand development and media relations. He will even support investor relations in association with Insys CFO, Andrew Long, and Chief Executive Officer and President, Saeed Motahari.

Alpha IR marks as an investor relations consulting entity, whose leadership team brings combined Wall Street experience of more than 100 years. Its healthcare specialists will support the development of the firm’s engagement plan with the investment community and offer current communications support and strategic messaging to both external and internal stakeholders.

Motahari expressed that McGrath is a remarkable addition to the Insys team, and he is confident that his extensive understanding and experience of the healthcare division will complement their new leadership team. As of now, his focus will be on assisting Insys to develop, maintain and establish principled and strong associations with company’s major stakeholders.

In addition, their association with Alpha IR is also a vital milestone for the firm, as Insys seek to improve investor relations effort. Motahari concluded that they considerably appreciate the support they obtained from In-Site Communications throughout their transition from a privately held firm to a publicly traded firm.

In the last trading session, the stock price of Insys declined 0.34% to close the day at $8.87. The market cap of firm now stands at around $644 million.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement